PATENT CLAIM ANALYSIS

Application Number: 16125991
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "380000"]

Abstract:
In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I′) forms.

Claim (Index 22):
A method of increasing atrial natriuretic peptide (ANP) or cyclic guanosine monophosphate (cGMP) levels in a human for at least 24 hours, the method comprising administering to the human an ANP or cGMP-increasing amount of (2S,4R)-5-(5\u2032-chloro-2\u2032-fluoro-[1,1\u2032-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid (Compound I) or crystalline free acid form of (2S,4R)-5-(5\u2032-chloro-2\u2032-fluoro-[1,1\u2032-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid (Compound I\u2032) once-daily.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 97.0
- Lexical Diversity: 1.65116
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15452333', '15040481', '15042391', '14812095', '13767285']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7511003005162364
- 35 USC 102 Novelty (BERT): 0.5493137157812761
- Combined Prediction Score: 0.7309216420427405
- Mean Citation Score: 324.98591
- Max Citation Score: 400.483
- Similarity Product: 294.43901153558494

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test